Stable injectable compositions of glp-2 peptide
US-2024415933-A1 · Dec 19, 2024 · US
Osmotic delivery comprising an insulinotropic peptide and uses thereof
US8940316B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8940316-B2 |
| Application number | US-92743210-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 15, 2010 |
| Priority date | Feb 3, 2005 |
| Publication date | Jan 27, 2015 |
| Grant date | Jan 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. An osmotic delivery device, comprising, a reservoir having a first and second ends; a piston within the reservoir, wherein the piston separates an osmotic engine compartment from a drug reservoir compartment; the osmotic engine compartment containing an osmotic agent formulation; the drug reservoir compartment containing a suspension formulation, the suspension formulation comprising, a particle formulation comprising an insulinotropic peptide, a disa…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8940316B2 cover?
- A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein…
- Who is the assignee on this patent?
- Alessi Thomas R, Mercer Ryan D, Rohloff Catherine M, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/26. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).